ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0626

Impact of the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) in Systemic Lupus Erythematosus Patients from the Almenara Lupus Cohort

Manuel Ugarte-Gil1, RV, Gamboa-Cardenas2, Victor Pimentel-Quiroz3, Cristina Reategui4, Claudia Elera Fitzcarrald5, Samira García-Hirsh6, José Alfaro-Lozano6, Cesar Pastor-Asurza6, Zoila Rodriguez-Bellido6, Risto Perich-Campos6 and Graciela Alarcon7, 1Universidad Cientifica del Sur, Lima, Lima, Peru, 2Universidad Científica del Sur, Lima, Lima, Peru, 3Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, 4Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, 5Hospital Nacional Guillermo Almenara Irigoyen/Universidad San Ignacio de Loyola, Lima, Peru, 6Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima, Peru, 7The University of Alabama at Birmingham, Oakland, CA

Meeting: ACR Convergence 2024

Keywords: Disease Activity, quality of life, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Physician-reported disease activity has a modest association with patient-reported outcomes (PROs) in systemic lupus erythematosus patients. The aim of this study is to evaluate the impact of patient-reported disease activity in other patient-reported outcomes.

Methods: We evaluated patient-reported disease activity on SLE patients from the Almenara Lupus Cohort. Disease activity was assessed using the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) PRO which ranges between 0 and 1200 (the higher the score is, the worse the activity is); health-related quality of life (HRQoL) was ascertained using the LupusQoL which ranges between 0 and 100 (the higher the score is, the better the HRQoL); fatigue was ascertained using the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F), which ranges between 0 and 52 (the higher score, the lower fatigue); and work productivity impairment was ascertained with the work productivity and activity impairment (WPAI) which ranges between 0 and 100 (the higher score, the higher disability). Generalized estimating equations were performed for each domain of the LupusQoL, the FACIT-F and the WPAI and the LFA-REAL PRO measured at the previous visit; multivariable models were adjusted for possible confounders (age at diagnosis, gender, educational level, socioeconomic status, disease duration, SLEDAI-2K, SDI, prednisone dose, antimalarials and immunosuppressive drug use and the same domain of the outcome variable)measured at the same visit as the LFA-REAL PRO. B was reported per 10 units increase of the LFA-REAL PRO.

Results: A total of 311 patients and 1116 visits were included. Of them, 289 (91.5%) were women, mean age at diagnosis was 34.6 (13.6) years. Mean (SD) LFA-REAL PRO at baseline was 240.9 (182.1). LFA-REAL PRO predicted a worse PRO in all domains of the LupusQoL, the FACIT-F and the WPAI, even after adjustment by possible confounders (table 1).

Conclusion: A higher patient-reported disease activity predicted a worse HRQoL and fatigue as well as a higher work productivity impairment in SLE patients, even after adjustment for possible confounders. Patient-reported disease activity should be included in the evaluation of SLE patients on a regular basis.

Supporting image 1


Disclosures: M. Ugarte-Gil: AstraZeneca, 1, 6, Ferrer, 1, GlaxoSmithKlein(GSK), 6, Janssen, 5, Tecnofarma, 2, 6, 12, Travel Support; R. Gamboa-Cardenas: None; V. Pimentel-Quiroz: None; C. Reategui: None; C. Elera Fitzcarrald: None; S. García-Hirsh: Adium, 1, 2, 3, 6; J. Alfaro-Lozano: None; C. Pastor-Asurza: None; Z. Rodriguez-Bellido: None; R. Perich-Campos: None; G. Alarcon: None.

To cite this abstract in AMA style:

Ugarte-Gil M, Gamboa-Cardenas R, Pimentel-Quiroz V, Reategui C, Elera Fitzcarrald C, García-Hirsh S, Alfaro-Lozano J, Pastor-Asurza C, Rodriguez-Bellido Z, Perich-Campos R, Alarcon G. Impact of the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) in Systemic Lupus Erythematosus Patients from the Almenara Lupus Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/impact-of-the-lupus-foundation-of-america-rapid-evaluation-of-activity-in-lupus-lfa-real-patient-reported-outcome-pro-in-systemic-lupus-erythematosus-patients-from-the-almenara-lupus-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-the-lupus-foundation-of-america-rapid-evaluation-of-activity-in-lupus-lfa-real-patient-reported-outcome-pro-in-systemic-lupus-erythematosus-patients-from-the-almenara-lupus-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology